Evercore ISI Group Maintains Outperform on Ascendis Pharma, Raises Price Target to $356
Benzinga Newsdesk 12 hours ago
Analyst RatingsNewsPrice Target
Evercore ISI Group analyst Josh Schimmer maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price target from $326 to $356.
Evercore ISI Group analyst Josh Schimmer maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price target from $326 to $356.